Evidence map›Paper›PMID 25701083›Full record

ReviewGastroenterology2015

Screening for Barrett's Esophagus.

Massimiliano di Pietro, Daniel Chan, Rebecca C Fitzgerald, Kenneth K Wang

Abstract readReview
In one paragraph

Review in Gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Barrett's Esophagus: An Updated Review.Diagnostics (Basel, Switzerland) · 2023
    Review
  6. Article
  7. Review
  8. Risk Prediction of Barrett's Esophagus in a Taiwanese Health Examination Center Based on Regression Models.International journal of environmental research and public health · 2021
    Article
  9. Article
  10. Drivers of Esophageal Adenocarcinoma and Opportunities for Cancer Interception.Cellular and molecular gastroenterology and hepatology · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Preferences for Surveillance of Barrett's Oesophagus: a Discrete Choice Experiment.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2019
    Article
  18. Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Massimiliano di PietroMRC Cancer Unit, University of Cambridge, Cambridge, England.
Daniel ChanBarrett's Esophagus Unit, Mayo Clinic, Rochester, Minnesota.
Rebecca C FitzgeraldMRC Cancer Unit, University of Cambridge, Cambridge, England. Electronic address: rcf29@mrc-cu.cam.ac.uk.
Kenneth K WangBarrett's Esophagus Unit, Mayo Clinic, Rochester, Minnesota. Electronic address: wang.kenneth@mayo.edu.
Mayo Clinic · USUniversity of Cambridge · GB

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Weight loss-induced Microbiome and Adipokine Changes in Barrett's EsophagusU54CA163004 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABRAMS, JULIAN, RUSTGI, ANIL K · 2011 to 2022
$12.5M
Validation & Pathology CoreU54CA163059 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RUBENSTEIN, JOEL H, WANG, THOMAS D · 2011 to 2022
$12.1M
Esophageal Cancer from Cells to Population: A Multiscale ApproachU01CA182940 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HUR, CHIN, INADOMI, JOHN MATTHEW · 2013 to 2017
$3.3M
Cancer Research UK 12088Medical Research Council MC_UU_12022/2NCI NIH HHS P30 CA015083NCI NIH HHS U01 CA182940NCI NIH HHS U54 CA163004NCI NIH HHS U54 CA163059
6 · The paper itself

Abstract

The large increase in the incidence of esophageal adenocarcinoma in the West during the past 30 years has stimulated interest in screening for Barrett's esophagus (BE), a precursor to esophageal cancer. Effective endoscopic treatments for dysplasia and intramucosal cancer, coupled with screening programs to detect BE, could help reverse the increase in the incidence of esophageal cancer. However, there are no accurate, cost-effective, minimally invasive techniques available to screen for BE, reducing the enthusiasm of gastroenterologists. Over the past 5 years, there has been significant progress in the development of screening technologies. We review existing and developing technologies, new minimally invasive imaging techniques, nonendoscopic devices for cell collection, and biomarkers that can be measured in blood or stool samples. We discuss the status of these approaches, data from clinical studies of their effects, and their anticipated strengths and weaknesses in screening. The area is rapidly evolving, and new tools will soon be ready for prime time.

Indexed as

Mass ScreeningAdenocarcinomaBarrett EsophagusBiomarkersBiopsyCapsule EndoscopyEquipment DesignEsophageal NeoplasmsEsophagoscopesEsophagoscopyHumansPrecancerous ConditionsPredictive Value of TestsRisk AssessmentRisk FactorsBiomarkersBiomarkersBiophotonicsCytologyEndoscopyFISH

Identifiers

PMID25701083
PMCPMC4703087
OpenAlexW2095317519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.